Extract from Baillie
Rhinomed is undervalued on our numbers, with a base case valuation
of $0.13 per share and optimistic case of $0.44 on a probability-weighted
DCF valuation. Our target price sits near our base case.
They have to be joking. They cannot even get the current sp correct. It closed at 2.6c on Nov 17th not 3cents as published.
Go for it guys buy up big. Maybe brokers want to offload?
- Forums
- ASX - By Stock
- RNO
- Broker Valuations
Broker Valuations, page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
MTL
Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus
Add RNO (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online